Kornimate/medical-research-clean huggingface dataset:
vitamin d and blood pressure

Conditions: Hypertension

Summary: vitamin d is a natural nutrient in normal daily diet. it can also be made in the skin after exposure to sunlight and is essential for maintaining normal calcium balance. one past study has suggested that vitamin d may be helpful for blood pressure. this study will test whether pills containing cholecalciferol (a form of vitamin d) or calcitriol (the active form of vitamin d) can treat high blood pressure. the investigators plan to enroll up to 80 subjects at the atlanta va medical center. participation in the study is expected to last up to 4 weeks. subjects will be assigned to cholecalciferol, calcitriol or placebo). a 24-hour blood pressure monitor will be worn at the beginning and end of the study to determine blood pressure changes. renin, pth, angiotensin-ii, and aldosterone levels will also be measured at the beginning and end of the study.


Eligibility criteria:
inclusion criteria: * participants must be over the age of 18 * vitamin d levels between 10 and 30 ng/ml * systolic blood pressure between 130 and 150 mmhg exclusion criteria: * current use of anti-hypertensive medication * inability to understand the consent form * inability to return abp monitor within 24-48 hours after visit * alcohol dependence * diagnosis of chronic kidney disease * history of heart disease * history of stroke * inability to comply with study protocol * current treatment for cancer * narcotic dependence * current use of greater than 2000 iu of vitamin d * pregnant

Keywords: vitamin d blood pressure hypertension vitamin d insufficient systolic blood pressure between 130 and 150 mmhg
an observational study investigating the effectiveness of pravastatin on renal function in korean dyslipidemic patients with type 2 diabetes

Conditions: Dyslipidemia Associated With Type II Diabetes Mellitus

Summary: this study investigated the effectiveness of pravastatin on renal function in korean dyslipidemic patients with type 2 diabetes.

this survey study investigated the effect of routine initiation single dose of pravastatin (10 mg, 20 mg, or 40 mg) on renal function in korean dyslipidemic patients with type 2 diabetes. the study also examined the effect of pravastatin on lipid profiles, glucose metabolism, and safety.

Eligibility criteria:
inclusion criteria: * participants with type 2 diabetes (currently using an antidiabetic drug or satisfying diagnostic criteria of diabetes as defined by american diabetes association) * participants with dyslipidemia (currently using an antidyslipidemic drug or satisfying the health insurance review \& assessment service insurance coverage treatment criteria\*) for whom drug treatment with pravastatin is confirmed * participants determined to be eligible as subjects at the discretion of the investigator * participants who voluntarily provided written consent using the informed consent form on use of information exclusion criteria: * participants who had administered pravastatin prior to study participation * participants with hypersensitivity to the investigational product or its history * participants with an active liver disease or persistent elevation of transaminase with an unknown cause * pregnant woman or women with childbearing potential, breastfeeding mothers * children * participants with severe hepatic or renal insufficiency * participants with myopathy * participants with cholestasis * participants with hypercholesterolemia due to hyperalphalipoproteinemia accompanied by hdl cholesterol elevation * participants with a genetic problem such as galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption

Keywords: dyslipidemia type ii diabetes mellitus
evaluation of soft multifocal lenses in presbyopic previous contact lens wearers

Conditions: Presbyopia

Summary: to explore the wear experience in dailies total1 multifocal contact lenses in presbyopic adults who have previously dropped out of contact lens wear.

the purpose of this study is to evaluate the wear experience of people with presbyopia who previously dropped out of contact lens wear when fit with a delefilcon a soft lens multifocal lens. investigators expect to enroll a relatively equal amount of former soft multifocal contact lens wearers who dropped out due to poor vision at distance or near and single vision wearers who dropped out due to poor near vision. the key endpoints include visual analog scale survey of lens wear symptoms (comfort, dryness, vision) with contact lenses and assessment of the participant's quality of life with the dailies total1 multifocal® contact lenses.

Eligibility criteria:
inclusion criteria: * ability to give informed consent. * any gender. * any racial or ethnic origin. * at least 38 years of age or older. * willing to spend time for the study. three visits are required to complete the study, and additional follow up visits could be scheduled if needed. * subjects must have corrected distance visual acuity in both eyes equivalent to 20/25 or better at the screening visit. * spectacle sphere power range between +6.00 to -10.00. * previously dropped out of contact lens wear due to vision or vision and discomfort. * good general health (defined by medication use that has not changed within the last month and the absence of medical conditions or treatments that are deemed confounding to the data as determined by the pi exclusion criteria: * current or active ocular inflammation or infection as determined by the investigator. * astigmatism ≥ 1.00 d in either eye. * history of previous eye surgery. * strabismus or binocular vision abnormalities that prevent completion of testing, at the discretion of the investigator. * demonstration or history of corneal ectasia or keratoconus. * pregnant or lactating

Keywords: contact lenses multifocal contact lenses
osteofibrous dysplasia (kempson-campanacci's disease)

Conditions: Osteofibrous Dysplasia

Summary: the aim of the present study is to obtain long term follow-up in patients with osteofibrous dysplasia, to assess natural history of the disease, late results of treatment and in particular the potential and risk of progression to adamantinoma.


Eligibility criteria:
inclusion criteria: * male and female patients treated at rizzoli institute from 01 jan 1943 to 31 dic 2011 * diagnosis of osteofibrous dysplasia pathologically confirmed * written informed consent prior to any study-specific analysis and/or data collection exclusion criteria: * patients with histological diagnosis different from osteofibrous dysplasia
topical antibiotic irrigation (gentamicin) in prophylaxis of midfacial fracture surgical wounds

Conditions: Surgical Site Infection

Summary: the purpose of this study is to evaluate the use of topical antibiotic irrigation (gentamycin) and its ability to reduce surgical site infections in midfacial fracture surgery compared to sterile normal saline (ns). previously, this study evaluated a different antibiotic, bacitracin, but in april of 2020 the study was modified to use gentamycin rather than bacitracin, after the fda warning of the toxic side effects of bacitracin and because the hospital where the study was conducted removed bacitracin from its formulary.


Eligibility criteria:
inclusion criteria: * patients who are planned for open reduction internal fixation of midfacial fractures as part of standard of care * patients who are admitted to memorial hermann hospital at texas medical center * able to sign their own consent exclusion criteria: * infected surgical sites * allergies to bacitracin
use of 2-octyl-cyanoacrylate together with a self-adhering mesh

Conditions: Surgical Wound Dehiscence; Cutis Laxa; Wound of Skin

Summary: the investigators prospectively studied the results of wound closure after abdominoplasty with randomized use of prineotm and conventional suturing to assess the possible difference in outcome between these two methods.follow-up visits to the outpatient clinic were scheduled at 2 weeks, 6 months and 12 months after surgery. a panel consisting of three plastic surgeons and three plastic surgery residents assessed the wound and scar appearance during the three follow-up visits.

abdominoplasty is one of the most commonly performed procedures in plastic surgery. the appearance of the scar is a major factor contributing to the aesthetic outcome of the procedure and depends largely on the technique of wound closure. the new prineotm wound closure system was introduced to combine the effectiveness of 2-octyl-cyanoacrylate (dermabond tm) together with a self-adhering mesh.fifty-two women and 8 men aged between 21 and 65 years scheduled for abdominoplasty were included in the study. total operating time after abdominoplasty between the traditional wound closure technique and the prineotm-type wound closure technique was compared. two weeks postoperatively, the wounds were examined and graded according to the hollander cosmesis scale. at 6- and 12-month follow-up, the aesthetic outcome of the abdominal scar was evaluated with the vancouver scar scale. twelve months postoperatively, the patients were further asked to score their part of the patient scar assessment scale.there was a statistically significant shorter mean of total operating time for the new skin closure system compared with intradermal sutures. the hollander cosmesis scale indicated a significantly more favourable overall result with prineotm at 2 weeks after surgery. the vancouver scar scale demonstrated a better cosmetic outcome in favour of prineotm 6 and 12 months after surgery the patient scar assessment scale scores 12 months after surgery indicated that the patients noted significantly less pain, thickness and irregularity with prineotm.based on our results, we conclude that prineotm is a safe and effective substitute for superficial skin closure, with good cosmetic results and no increase in wound complications. the use of prineotm decreases operative times and costs and enhances patients' postoperative comfort.

Eligibility criteria:
inclusion criteria: * patients who underwent an abdominoplasty without exclusion criteria exclusion criteria: * current intake of systemic steroids * known hiv-positive or other immunocompromised status * known or suspected allergy or sensitivity to cyanoacrylate, formaldehyde, tapes or adhesives * personal or family history of keloid or hypertrophic scar formation

Keywords: abdominoplasty, skin closure, dressings
impact of a hospital pharmacist's intervention on feno (fractional exhaled nitric oxide) in asthmatic patients

Conditions: Asthma

Summary: the impact of a pharmacist's intervention on asthma control has now been well demonstrated, but its effect on inflammatory markers of feno (fractional exhaled nitric oxide) in asthmatic patients has been little studied in the literature. the aim of this study is to investigate the impact of a pharmacist's intervention on feno in patients seen in clinical practice by a pneumologist in a secondary university center.


Eligibility criteria:
inclusion criteria: * adult asthmatics (definition of asthma: fev1 \[forced expiratory volume in 1 second\] reversibility of at least 12% and 200 ml after 400 mcg of salbutamol and/or pc20m \[provocative concentration of methacholine causing a 20% fall in fev1\]\<16 mg/ml) * unchanged or increased dose of inhaled corticosteroids prescribed by the pneumologist at the visit * feno (fractional exhaled nitric oxide) \> or = 25 ppb exclusion criteria: * treatment with oral corticosteroids to treat an asthma exacerbation within 4 weeks before the visit with the pneumologist exclusion criteria during the study: * change of the dose of ics (inhaled corticosteroids) during the follow-up of 3 months after the pharmacist's intervention * severe asthma exacerbation requiring oral corticosteroids within the 4 weeks before the follow-up visit (3 months after the pharmacist's intervention)
effect of compound amino acid tablets on nutritional status of patients with lung cancer

Conditions: Amino Acid Deficiency; Malnutrition; Lung Cancer

Summary: to investigate whether compound amino acid supplementation can further promote protein synthesis and improve nutritional status for lung cancer patients.


Eligibility criteria:
inclusion criteria: * nrs2002 \>=3 scores * lung cancer patients * low albumin or hemoglobin * informed consent exclusion criteria: * acute and critical patients; * severe liver and kidney dysfunction; * patients with gastrointestinal bleeding or intestinal obstruction; * pregnant women, lactating women, people with mental illness, and people without independent behavior ability.
natural history of netherton syndrome

Conditions: Netherton Syndrome

Summary: the goal of this non-interventional study (nis) is to collect real-world data to describe the natural history of netherton syndrome (ns).


Eligibility criteria:
inclusion criteria \[for part 1 and part 2\] 1. confirmed diagnosis of ns by at least one of the following: * genetic testing of mutations in serine protease inhibitor of kazal type 5 (spink5); * absence or major deficiency of the protein lympho-epithelial kazal-type-related inhibitor (lekti) in skin biopsy; * clinical assessment (signs and symptoms). 2. provision of consent or assent (i.e., by parent or legal guardian) as required by local regulations: * \[part 1\] to authorise access to existing medical records for study data collection; * \[part 2\] to participate in the longitudinal 52-week evaluation of disease severity and clinical outcome assessments. \[for part 2 only\] 3. not participating in a clinical trial at the time of study enrolment for part 2. exclusion criteria \[for part 1 and part 2\] 1. patient who has died prior to 2002. 2. patient whose last known survival status is dated prior to 2002 (i.e., patient has been lost to clinical follow-up since 2002).
clinical evaluation of fortilink® tetrafuse® interbody fusion device in subjects with degenerative disc disease

Conditions: Degenerative Disc Disease

Summary: this is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the fortilink ibf system with tetrafuse 3d technology.

this is a prospective, multi-center, non-randomized post-market evaluation designed to collect and evaluate data on the safety and performance of the fortilink ibf system with tetrafuse 3d technology. there will be 3 arms in the study, one for each configuration of the fortilink ibf system (fortilink-c, fortilink-ts and fortilink-l). up to 50 subjects will be enrolled in each study arm for a total of up to 150 subjects at up to 20 sites in the united states (us) and european union (eu).

Eligibility criteria:
inclusion criteria: * the subject is skeletally mature and at least 18 years of age. * the subject has degenerative disc disease (ddd) of the cervical spine with accompanying radicular symptom at one or two contiguous levels (fortilink-c), or the subject has ddd and ≤ grade 1 spondylolisthesis of the lumbar spine at one or two contiguous levels (fortilink-ts and fortilink-l). * subject plans to undergo one of the following procedures: an anterior cervical interbody fusion at one to two continuous levels from c2-c3 to c7-t1 using autogenous or allogenic bone graft and supplemental fixation cleared and indicated for use at the proposed treatment level(s) (fortilink-c), or an interbody fusion in the lumbar spine at one to two continuous levels from l1-l2 to l5-s1 using autogenous or allogenic bone graft and supplemental fixation cleared and indicated for use at the proposed treatment level(s) (fortilink-ts and fortilink-l). * the subject has undergone non-operative treatment of at least six weeks (fortilink-c) or at least six months (fortilink-ts and fortilink-l) prior to treatment with the ibf system. * the subject is willing and able to provide informed consent. * the subject is willing and able to attend the protocol required follow-up visits and examinations. exclusion criteria: * the subject has an active infection * the subject has had prior fusion attempt(s) or is undergoing revision of a previously implanted system at the involved level(s). * the subject is a worker's compensation case, in active litigation related to the procedure or is a prisoner or ward of the state. * the subject meets one or more of the contraindications outlined in the ifu. * the subject is pregnant, nursing, or is planning to become pregnant in the next year. * the subject has documented evidence of current substance abuse. * the subject has other concurrent medical condition that, in the opinion of the investigator, does not make the subject a good candidate for the study.
study on aunip as a novel tumor marker for cervical cancer

Conditions: Cervical Cancer

Summary: to detect the expression of aunip in cervical cancer serum, and to clarify its diagnostic and prognostic value.

blood of all study participants of cervical cancer patients are collected to detect the expression of aunip, analyze the statistical correlation between the expression of cervical cancer aunip and clinicopathological parameters of patients, and preliminarily understand the expression of aunip in cervical cancer tumor tissues and its clinical diagnostic and progniostic value.

Eligibility criteria:
inclusion criteria: study group inclusion criteria: * women aged 20-60 * there is a definite pathological diagnosis of cervical cancer healthy control group: * women aged 20-60 * no tumors in the uterus or other parts of the body * no inflammatory disease * blood routine and blood biochemical tests are normal exclusion criteria: exclusion criteria of the study group: * there are other lesions in the uterus and uterine adnexa exclusion criteria of healthy control group: * pregnant, lactating or menarche women * women who are undergoing human papillomavirus (hpv) vaccination
effect of nitroglycerin hydrogel on repairing critical bone defects

Conditions: Bone Regeneration; Periodontal Bone Loss; Healing Fracture of Bone

Summary: due to their osteoconductive, osteoinductive, and osteogenic qualities, autologous bone grafts are the gold standard for augmenting bone, (1). however, problems, insufficient bone quantity, and/ or quality at the donor location could prevent it from being used. consequently, a variety of bone graft materials, such as allografts and/or xenografts, were developed to improve bone development and provide an osteoconductive matrix in the so-called hard tissue critical-size defect (csd) (2). "critically-sized" defect is regarded as one that would not heal spontaneously despite surgical stabilization and requires further surgical intervention (3). the management of critical-sized bone defects remains a major clinical orthopedic challenge. critical-sized bone defects are technically defined as those that will not heal spontaneously during the patient's lifetime. bone loss greater than 2 times the diameter of the long bone diaphysis is unlikely to result in union despite appropriate stabilization methods (4). nitroglycerin, also known as glyceryl trinitrate (gtn), is a medication commonly used to treat heart conditions like angina pectoris and chronic heart failure. it acts as a potent vasodilator, dilating the vascular system to improve blood flow. nitroglycerin has been found to have a positive effect on bone formation. studies indicate that nitroglycerin when applied topically, can increase bone formation and reduce bone resorption. this effect is achieved through the stimulation of osteoblastic differentiation and proliferation (5). the mechanism of action of nitroglycerin in bone formation involves its conversion into nitric oxide (no), which plays a crucial role in stimulating bone formation. nitric oxide released from nitroglycerin acts as a signaling molecule that enhances osteoblastic differentiation and proliferation of bone marrow-derived mesenchymal stem cells. this process leads to increased bone mineral density, improved bone geometry, and enhanced bone strength (5). hydrogels are natural or synthetic biocompatible polymers that are widely used in periodontal tissue engineering as a delivery material for different biologics (6). synthetic hydrogels have superiority in chemical and mechanical properties over natural hydrogels (7). carbopol or polyacrylic acid (paa) is one of the most widely used polymers as a hydrogel. it is an anionic polyelectrolyte that can be readily polymerized and crosslinked to form hydrogels with a swelling capacity greater than their dry weight (8).

aim of the study histomorphometric analysis of regenerative capacity of nitroglycerin-loaded hydrogel in management of critical size bone defect in experimental study. materials and methods

Eligibility criteria:
inclusion criteria: * all animals were adult with an age ranging between 3 to 7 months and a weight ranging between 250 and 350 g exclusion criteria: * other than inclusion

Keywords: nitroglycerin, bone regeneration critical size defect
effect of expression of cd74 and vegf on outcome of treatment in patients with malignant pleural mesothelioma

Conditions: Malignant Pleural Mesothelioma

Summary: this is a prospective study evaluating the effect of expression of cd74 and vegf on outcome of treatment in patients with malignant pleural mesothelioma receiving pemetrexed/platinum protocol. the paraffin blocks of the patients will be tested for cd74 and vegf before starting treatment using ihc and the results will be correlated with the outcome of treatment during evaluation.


Eligibility criteria:
inclusion criteria: 1. histologic or cytologic diagnosis of malignant pleural mesothelioma 2. no prior chemotherapy. 3. ecog less than or equal to 2 . 4. measurable disease according to the requirements of swog criteria. 5. age ≥ 19 years . 6. estimated life expectancy of at least 12 weeks . 7. adequate bone marrow reserve (white blood cells \[wbc\] ≥ 3.5 × 109 /l, neutrophils ≥ 1.5 × 109 /l, platelets ≥ 100 × 109 /l, and hemoglobin ≥ 9.0 gm/dl). exclusion criteria: 1. presence of central nervous system metastases. 2. inadequate liver function (bilirubin \> 1.5 times upper normal limit \[unl\] and alanine transaminase \[alt\] or aspartate transaminase \[ast\] \> 3.0 unl or up to 5.0 unl in the presence of hepatic metastases). 3. inadequate renal function (creatinine \> 1.25 times unl, creatinine clearance \< 50ml/min). 4. serious concomitant systemic disorder incompatible with the study. 5. second primary malignancy (except in situ carcinoma of the cervix, adequately treated basal cell carcinoma of the skin, t1 vocal cord cancer in remission, or prior malignancy treated more than 5 years prior to enrollment without recurrence). 6. pregnancy

Keywords: mesothelioma cd 74 vegf